AU2001290704A1 - Antisense modulation of caspase 9 expression - Google Patents

Antisense modulation of caspase 9 expression

Info

Publication number
AU2001290704A1
AU2001290704A1 AU2001290704A AU9070401A AU2001290704A1 AU 2001290704 A1 AU2001290704 A1 AU 2001290704A1 AU 2001290704 A AU2001290704 A AU 2001290704A AU 9070401 A AU9070401 A AU 9070401A AU 2001290704 A1 AU2001290704 A1 AU 2001290704A1
Authority
AU
Australia
Prior art keywords
caspase
expression
antisense modulation
antisense
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290704A
Inventor
Andrew T. Watt
Hong Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2001290704A1 publication Critical patent/AU2001290704A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001290704A 2000-09-11 2001-09-10 Antisense modulation of caspase 9 expression Abandoned AU2001290704A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/659,845 US6492170B1 (en) 2000-09-11 2000-09-11 Antisense modulation of caspase 9 expression
US09659845 2000-09-11
PCT/US2001/028233 WO2002022641A1 (en) 2000-09-11 2001-09-10 Antisense modulation of caspase 9 expression

Publications (1)

Publication Number Publication Date
AU2001290704A1 true AU2001290704A1 (en) 2002-03-26

Family

ID=24647062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290704A Abandoned AU2001290704A1 (en) 2000-09-11 2001-09-10 Antisense modulation of caspase 9 expression

Country Status (3)

Country Link
US (2) US6492170B1 (en)
AU (1) AU2001290704A1 (en)
WO (1) WO2002022641A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254136A1 (en) * 2001-07-03 2004-12-16 Troy Carol M. Antisense oligonucleotides and related methods for regulating cell death
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1997046663A1 (en) * 1996-05-20 1997-12-11 Smithkline Beecham Corporation Interleukin-1 beta converting enzyme like apoptotic protease-6
US6010878A (en) 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
EP1084260B1 (en) * 1998-06-02 2007-11-28 Vertex Pharmaceuticals Incorporated Caspase-9 deficient animals and the use thereof
US6403765B1 (en) * 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
JP2002518449A (en) 1998-06-24 2002-06-25 メルク エンド カムパニー インコーポレーテッド Compositions and methods for treating high blood cholesterol
JP2002518457A (en) 1998-06-24 2002-06-25 メルク エンド カムパニー インコーポレーテッド Compositions and methods for inhibiting bone resorption
ATE257822T1 (en) 1998-07-08 2004-01-15 Harbor Branch Oceanographic AMINOIMINOCHINONE AND AMINOQUINONE ALKALOID COMPOUNDS AS CASPASE INHIBITORS
US6177565B1 (en) 1998-08-19 2001-01-23 Vertex Pharmaceuticals Inc. Process for synthesizing piperazic acid
JP2002527386A (en) 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド Bone formation regulation method

Also Published As

Publication number Publication date
US20030087871A1 (en) 2003-05-08
US6492170B1 (en) 2002-12-10
WO2002022641A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001229363A1 (en) Antisense modulation of caspase 3 expression
AU2002213002A1 (en) Antisense inhibition of caspase 6 expression
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU5239399A (en) Antisense modulation of g-alpha-13 expression
AU4576999A (en) Antisense modulation of tnfr1 expression
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2001229493A1 (en) Antisense modulation of mekk2 expression
AU4325199A (en) Antisense modulation of g-alpha-11 expression
AU2001289046A1 (en) Antisense modulation of her-2 expression
AU2002213467A8 (en) Modulation of ccr4 function
IL178864A0 (en) 3'-prodrugs of 2'-deoxy-??-l-nucleosides
AU2001239971A1 (en) Antisense modulation of parp expression
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU6115400A (en) Antisense modulation of mekk5 expression
AU2001288968A1 (en) Antisense modulation of btak expression
AU2001289068A1 (en) Antisense modulation of caspase 2 expression
AU2001227848A1 (en) Antisense modulation of caspase 8 expression
AU2002230869A1 (en) Antisense modulation of hepsin expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU2002226064A1 (en) Antisense modulation of talin expression